What alternative single‑inhaler triple therapy can be used for an adult with COPD instead of Trelegy (fluticasone furoate 500 µg + umeclidinium 62.5 µg + vilanterol 25 µg)?

Alternative Single-Inhaler Triple Therapies to Trelegy

For adults with COPD requiring single-inhaler triple therapy (SITT), the FDA-approved alternatives to Trelegy are budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM) and beclometasone dipropionate/formoterol/glycopyrronium (BDP/FOR/GLY), though real-world evidence suggests Trelegy (FF/UMEC/VI) demonstrates superior effectiveness in reducing exacerbations and mortality.

Available SITT Options

Three single-inhaler triple therapies are currently approved for COPD maintenance treatment 1:

• Trelegy Ellipta: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) - once daily
• Breztri Aerosphere: Budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM) - twice daily
• Trimbow: Beclometasone dipropionate/formoterol/glycopyrronium (BDP/FOR/GLY) - twice daily

All three contain the same drug classes (ICS/LAMA/LABA) but differ in specific molecules, dosing frequency, and delivery devices 1, 2.

Comparative Effectiveness Evidence

FF/UMEC/VI vs BUD/GLY/FORM

The most robust comparative data comes from a 2025 real-world study of 44,542 Medicare patients, which found FF/UMEC/VI users experienced 3:

• 12% lower rate of moderate-severe exacerbations (0.80 vs 0.91 per patient-year; RR 0.88, P<0.001)
• 10% lower risk of moderate-severe exacerbations at 12 months (HR 0.90, P<0.001)
• 11% lower risk of all-cause mortality at 12 months (5.6% vs 6.4%; HR 0.89, P=0.020)

These findings were consistent across different insurance populations and particularly pronounced in patients stepping up from dual therapy, where FF/UMEC/VI showed an 18% lower exacerbation rate 4.

FF/UMEC/VI vs BDP/FOR/GLY

A 2026 Taiwanese population study of 12,971 patients found FF/UMEC/VI associated with 5:

• 20% lower risk of severe exacerbations (HR 0.80)
• 20% lower risk of moderate exacerbations (HR 0.80)
• Marginally lower pneumonia risk (HR 0.85, not statistically significant)

However, among patients maintaining therapy ≥90 days (73% of initiators), differences became minimal except for moderate exacerbations, suggesting comparable long-term effectiveness in adherent patients 5.

Clinical Decision Algorithm

For patients requiring SITT (high exacerbation risk: ≥2 moderate or ≥1 severe exacerbation/year with FEV1 <80% predicted) 6:

1. First-line recommendation: FF/UMEC/VI (Trelegy)

   • Once-daily dosing improves adherence
   • Strongest mortality benefit evidence
   • Superior exacerbation reduction in head-to-head comparisons

2. Alternative if FF/UMEC/VI contraindicated or unavailable:

   • BUD/GLY/FORM (Breztri) - preferred second choice based on available comparative data
   • BDP/FOR/GLY (Trimbow) - extrafine formulation may benefit small airway disease

3. Consider BDP/FOR/GLY specifically for:

   • Patients requiring extrafine particle formulation for peripheral airway targeting
   • Those with prior success on beclometasone-based therapy

Important Caveats

ICS Dose Considerations

The 2023 Canadian Thoracic Society guidelines emphasize that moderate ICS doses (not high doses) provide optimal benefit 6. The ETHOS trial showed mortality benefit with budesonide 320 µg but not 160 µg, though exacerbation reduction was similar 6. High ICS doses increase pneumonia risk without additional benefit for most outcomes.

Pneumonia Risk

All ICS-containing triple therapies carry increased pneumonia risk (class effect), with number needed to harm of 33 patients/year versus number needed to treat of 4 patients/year to prevent one exacerbation 6. This favorable risk-benefit ratio supports triple therapy use despite pneumonia concerns.

Single vs Multiple Inhalers

Guidelines strongly favor SITT over multiple-inhaler triple therapy due to improved adherence, reduced technique errors, and potentially superior outcomes 6. Never prescribe triple therapy components in separate inhalers when SITT is available.

Contraindications

All triple therapies are contraindicated in 7:

• Severe milk protein hypersensitivity
• Asthma without ICS (LABA monotherapy increases asthma mortality)
• Acute COPD deterioration (not for rescue use)

Drug Interactions

Exercise caution with 7:

• Strong CYP3A4 inhibitors (ketoconazole) - may cause cardiovascular effects
• MAO inhibitors/tricyclic antidepressants - potentiate cardiovascular effects
• Beta-blockers - may block bronchodilation
• Non-potassium-sparing diuretics - worsen hypokalemia
• Other anticholinergics - avoid concurrent use

Guideline-Based Indications

The 2023 CTS guidelines make a strong recommendation for LAMA/LABA/ICS triple therapy in patients with 6:

• High exacerbation risk (≥2 moderate or ≥1 severe exacerbation/year)
• High symptom burden (mMRC ≥2 or CAT ≥10)
• FEV1 <80% predicted
• Health status impairment

This recommendation prioritizes mortality reduction as the primary outcome, with additional benefits for dyspnea, health status, lung function, and exacerbation prevention 6.